Biora Therapeutics Says Notified Co That Its Securities Were Subject To Delisting From Nasdaq Unless Company Timely Requests Hearing Before Panel
Portfolio Pulse from Benzinga Newsdesk
Biora Therapeutics has been notified that its securities are subject to delisting from Nasdaq unless the company requests a hearing before a panel in a timely manner, according to an SEC filing.
June 14, 2024 | 8:34 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Biora Therapeutics has been notified that its securities are subject to delisting from Nasdaq unless the company requests a hearing before a panel in a timely manner.
The potential delisting from Nasdaq is a significant negative event for Biora Therapeutics, as it could lead to reduced liquidity and investor confidence. The company's stock price is likely to be negatively impacted in the short term unless they successfully request a hearing and resolve the issue.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100